Publish date:

Global Royalty Rate Trends In Pharma And Biotech Dealmaking 2021 Report

DUBLIN, Sept. 23, 2021 /PRNewswire/ -- The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021" report has been added to ResearchAndMarkets.

DUBLIN, Sept. 23, 2021 /PRNewswire/ -- The "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2021" report has been added to's offering.

This report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.This report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2021.The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.This report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners. Key Benefits

  • In-depth understanding of royalty rate partnering deal trends since 2010
  • Analysis of the structure of royalty clauses with numerous real life case studies
  • Comprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release
  • Comprehensive access to actual partnering deal contracts entered into by the world's life science companies where a royalty rate is disclosed
  • Insight into the royalty terms included in a licensing agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report Scope

Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide. Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 includes:

  • Trends in royalty rates in the biopharma industry since 2010
  • Analysis of royalty rate clause structure
  • Case studies of real-life licensing deals which disclose royalty rates
  • Comprehensive listing of licensing deals which disclose royalty rates since 2010
  • Access to licensing contract documents which disclose royalty rates
  • The leading licensing deals by royalty rate value since 2010
  • Most active royalty rate disclosures since 2010

In Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2021 available deals and contracts are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Key Topics Covered: Executive Summary Chapter 1 - Introduction1.1. What are royalties?1.2. History of royalty rates1.3. Royalties in pharma and biotech1.4. Royalties versus revenue share1.5. Overview of the report Chapter 2 - An overview of pharma and biotech royalty rates2.1. Trends in royalty rates 2010-20212.2. Royalty rate disclosure in pharma and biotech2.3. How do revenue shares figure?2.4. A review of recent literature2.5. Royalty rates in the future Chapter 3 - Average royalty rates for pharma and biotech partnering3.1. Royalty rates in early stage deals3.2. Royalty rates by stage of development3.3. Royalty rates by therapy area Chapter 4 - The royalty clause in pharma and biotech deals4.1. Partnering agreement structure4.2. Structure of a typical royalty clause4.3. Example royalty clauses4.3.1. Case study 1: Merck Serono-Opexa Therapeutics4.3.2. Case study 2: Aradigm - Grifols4.3.3. Case study 3: Forect Laboratories - Trevena4.3.4. Case study 4: Sage Therapeutics - University of California Chapter 5 - Companies actively disclosing royalty rates5.1. 25 most active companies in disclosing royalty rates5.2. Top partnering deals by royalty rate5.3. The role of bigpharma and bigbiotech in royalty rate disclosure5.2. Top partnering deals by royalty rate Chapter 6 - Royalty rate contract directoryExplore royalty rates within the deal contract document to gain greater insight AppendicesAppendix 1 - Royalty rates in deals - by company A-ZAppendix 2 - Royalty rates in deals - by therapy areaAppendix 3 - Royalty rates in deals - by stage of development at signingAppendix 4 - Royalty rates in deals - by technology typeAppendix 5 - Royalty rate referencesAppendix 6 - ResourcesAppendix 7 - Deal type definitionsAppendix 8 - Example royalty rate deal contract document

For more information about this report visit

Media Contact: Research and Markets Laura Wood, Senior Manager      

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets